The ChEMBL-og

There is a conference that we are presenting some new ChEMBL work and analysis at, and also there is a talk on CanSAR. The conference is at Bilkent University, in Ankara , Turkey. Dates are fairly soon though  - 17th and 18th October 2011, but there is still time to submit an abstract - I wish more conferences were like this, in not having a big gap between the conference and any deadlines for submission. The conference website is http://www.i-cancer.org/bioinformatics2011 . As an aside, I hadn't linked Ankara in Turkey before to the word Angora (Angora is an old name for Ankara), so this is the place responsible for the Angora goat, rabbit and cat!

Unfortunately Chris has cancelled his entire UK trip next week, due to a patent case being heard in the States that he is involved with. Subsequently his seminar on campus next week is also cancelled.

We have recently completed the legal formalities for an exciting collaborative grant involving the development of a service infrastructure for data from EU-funded research into non-animal tests for predicting chemical safety. - the grant is called DiXa. We are currently recruiting two positions for this grant (and there will be some additional posts later). These will be in the group of Ugis Sarkans at the EBI. Further details on the positions can be found here. Post 1 Post 2

There are a large number of antibody drugs in development - there are about 580 in the current ChEMBL list ( click here for Excel spreadsheet). I've stripped out some of the fields for clarity, but it should be pretty obvious what everything is. So, given that we'll start loading our biological drug sets into ChEMBL shortly, is there any key data missing, as always, any feedback on errors, etc would be greatly appreciated. If anyone would like a file of all the sequences that we have, let me know. A couple of notes on the data content There will be some duplication - due primarily to the INNs not being released with Research Code information, whereas from clinicaltrials.gov they typical enter via a Research Code name - after a few months the entries are linked. So any further information on this set would be greatly appreciated.... The Phase number refers to the highest phase I could find the antibody drug reaching in the broad literature - it does not capture cu...

A paper on ChEMBL has just been published in Nucleic Acids Review Database Issue. If NAR is new to you, it is the de facto place for publishing new (and updates to) online biological data sources. A link to the advance access   free, Open Access paper is here . %T ChEMBL: a large-scale bioactivity database for drug discovery %A A Gaulton %A LJ Bellis %A AP Bento %A J Chambers %A M Davies %A A Hersey %A Y Light %A S McGlinchey %A D Michalovich %A B Al-Lazikani %A JP Overington %J Nucleic Acids Research %D 2011 %O doi:10.1093/nar/gkr777

There is a new paper on ChEMBL just published in Biochem. Soc. Trans.  The paper itself is here (subscription required). %T Collation and data-mining of literature bioactivity data for drug discovery %A LJ Bellis %A R Akhtar %A B Al-Lazikani %A F Atkinson %A AP Bento %A J Chambers %A M Davies %A A Gaulton %A A Hersey %A K Ikeda %A FA Krueger %A Y Light %A S McGlinchey %A R Santos %A B Stauch %A JP Overington %J Biochem. Soc. Trans %V 39 %P 1365-1370 %D 2011

Things will be fairly quiet for the next week at ChEMBL Manor - we're off on our annual research retreat - this time to Kent. So please allow us a little more time to get back to emails, etc .